10 pharmaceutical companies are favored by capital, accelerating the development of innovative drugs

Recently, financing incidents in the pharmaceutical industry are still increasing
.
In the context of the rapid development of the innovative drug industry, related companies continue to be favored by the capital market
.
According to the author's incomplete statistics, since October, at least 10 pharmaceutical companies have won the favor of capital to accelerate the development of innovative drugs
.
Changyu Pharmaceutical: Completed US$40 million in Series C financing.
On November 5, it was reported that Changyu Pharmaceutical, an innovative drug company focused on the treatment of neurological diseases, completed US$40 million in Series C financing and was overraised
.
This round of financing was jointly led by SAIC Hengxu, CITIC Securities, and Hi-Tech Xinjun, with the participation of Yijing Capital, Jinshajiang, Runpu, and Daoyuan Capital.
The original shareholder Ping An Ventures continued to invest
.
It is reported that this round of financing will continue to be used to develop original dual-target molecules based on Changyu Pharmaceutical’s proprietary coupled drug technology platform, including XG005's upcoming phase III and phase II acute and chronic pain (including tumors) in the United States and China.
Pain, bone and joint pain) clinical trials, the second phase of overseas clinical trials of transdermal product XG004, and the promotion of other pipeline products
.
Horde Bio: Completed hundreds of millions of yuan in Series B financing On November 1, the innovative R&D company Horde Biosciences announced the completion of hundreds of millions of yuan in Series B financing.
This round of financing was led by Hillhouse Ventures, Eli Lilly Asia Fund and old shareholders Yuansheng Ventures followed suit
.
It is reported that this round of financing will be used to support the clinical trials of the first product, expand the existing iPSC cell therapy product R&D pipeline, and develop the GMP automated closed production system
.
Anjisheng Bio: Completed B round of US$70 million in financing.
On November 1st, Anjisheng Bio, which focuses on the research and development of innovative drugs for bone, joint and muscle diseases, announced the completion of the B round of US$70 million in financing
.
This round of financing was led by Morningside Venture Capital.
Legend Capital, Morning One Investment, China Merchants Bank International, Sanzheng Health Investment, Lichen Investment, Honghai Venture Capital and many other institutions participated in the investment.
The original investors Aobo Capital, Gao Ling Venture Capital, Guangzhou Junshi, Yuanhe Origin continue to participate in the investment and support
.
This round of financing will be used to continue to promote the development of domestic and foreign clinical research trials of multiple drug candidates including AGA111, continue to expand the scale of the preclinical product pipeline, and further improve the creation of a management team with international experience and vision.
Accelerate the industrialization of innovative drugs in the treatment of severe bone, joint and muscle diseases
.
Circle One Wisdom Ainnocence: Received tens of millions of yuan in the first round of financing.
On November 2nd, a biotechnology company dedicated to the research and development of AI innovative drugs, "Ainnocence," announced that the company has received tens of millions of yuan in the first round of financing.
For Yuansheng Capital
.
This round of financing will be mainly used to deepen platform technology, promote pipeline projects, and expand the talent team
.
Guoxin Pharmaceutical: Completed nearly 100 million yuan in Series B financing.
On October 28, the domestic clinical CRO company Guoxin Pharmaceutical announced that it has completed nearly 100 million yuan in Series B financing, which is invested by Puhua Capital, Jinhuifeng Investment and other institutions
.
It is reported that after the completion of this round of financing, the company will continue to deepen the clinical research and post-market research fields of innovative drugs
.
Sigma Biosciences: Receives nearly 10 million U.
S.
dollars in angel + round of financing.
On October 26, Sigma Biosciences, a cancer innovative targeted drug research and development company based on disease models, announced that the company has completed an angel + round of nearly tens of millions of dollars in financing.
Capital (formerly Morningside Capital) led the investment, Yayi Capital and Blue Ocean Capital followed suit, and old shareholders Tiantu Investment and Yunjiu Capital continued to raise their stakes
.
This round of financing will be used to accelerate the company's two innovative targeted drug R&D pipelines to advance to clinical trials, and at the same time promote the expansion and application of disease model platforms
.
Yimaike: Completed tens of millions of A round of financing On October 11, Yimaike, a digital industry service platform dedicated to the field of bio-innovative drugs, announced that it has recently completed tens of millions of A round of financing
.
The institutions participating in this round of investment include Longjin Investment, Shileng Investment, Haimaide Fund, and Fangfu Capital
.
It is reported that the funds raised will be used to provide application scenarios for accelerating the research and development of new drugs, enhancing the digital brand influence of pharmaceutical companies and the competitiveness of supply chain products around two types of B-end users in the bio-innovative drug company and the pharmaceutical industry supply chain.

.
Xianweida Bio: Completed 450 million yuan C round of financing.
On October 12, Xianweida Bio, which focuses on the development of new biomacromolecule drugs in the field of metabolic diseases, announced the completion of 450 million yuan C round of financing.
This round of financing was funded by Zhengxingu Capital, IDG Capital and the original investor, LYFE Capital, jointly invested
.
It is reported that this round of financing funds will be mainly used for international clinical research and follow-up product pipeline research and development of the company's existing projects
.
Changxi Pharmaceutical: Completed nearly 200 million yuan in Series C financing.
On October 11, Changxi Pharmaceutical, a biopharmaceutical company, announced the completion of nearly 200 million yuan in Series C financing.
This round of financing was led by Longpan Investment, China Merchants Securities Investment, Heda Capital co-investment, the existing shareholder Super Pro Rata (Super Pro Rata)
.
It is reported that this round of financing funds will be used to support the development of Changxi Pharmaceutical's innovative inhalation drug delivery products and external commercial cooperation
.
Bibet: Completed nearly 500 million yuan in equity financing On October 8, Bibet, which focuses on the research and development of original and innovative drugs for the treatment of cancer and other major diseases, announced that the company has completed nearly 500 million yuan in equity financing.
This round of financing is funded by Yingke Capital.
Leading the investment, the funds raised will accelerate the research and development of new cancer drugs such as small molecule drugs and nucleic acid drugs
.